Glucagon-like peptide 1 receptor agonist for endometrial neoplasms

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 6 Aug 2025: Trial registered, NCT07107334
  2. 7 Apr 2026: Trial started, NCT07107334

The trials

NCT07107334: A Study to Estimate Early Clinical Efficacy Signals of GLP-1 Agonist Administration in Conjunction With Levonorgestrel Intrauterine Device in Obese Patients With Endometrioid Intraepithelial Neoplasia

State
Under way
Phase
Phase 2
People
20 planned
Started
7 Apr 2026
Primary completion
Nov 2028
Arms
Glucagon-like peptide 1 receptor agonist
Results
None posted
  1. 6 Aug 2025: Trial registered
  2. 7 Apr 2026: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 2 trial

About the treatment

Kind of treatment: Drug.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.